NervGen Pharma (NASDAQ:NGEN) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of NervGen Pharma (NASDAQ:NGEN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.00.

Several analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of NervGen Pharma in a research report on Monday, November 2nd. Wall Street Zen upgraded shares of NervGen Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 24th.

View Our Latest Report on NervGen Pharma

NervGen Pharma Price Performance

NGEN stock traded up $0.25 during mid-day trading on Friday, hitting $1.88. The stock had a trading volume of 1,992,087 shares, compared to its average volume of 515,702. NervGen Pharma has a 52 week low of $1.28 and a 52 week high of $6.30. The stock has a market capitalization of $151.58 million and a price-to-earnings ratio of -4.09. The stock’s fifty day moving average is $1.74.

NervGen Pharma (NASDAQ:NGEN – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.28). As a group, analysts anticipate that NervGen Pharma will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On NervGen Pharma

Institutional investors have recently modified their holdings of the business. AXQ Capital LP bought a new stake in shares of NervGen Pharma during the 2nd quarter worth $89,000. Stonepine Capital Management LLC bought a new position in NervGen Pharma in the second quarter valued at about $559,657. Finally, Empery Asset Management LP bought a new position in NervGen Pharma in the second quarter valued at about $8,240,000.

About NervGen Pharma

(Get Free Report)

NervGen Pharma is a clinical-stage biotechnology company focused on developing treatments for nervous system injuries and diseases. The company’s research centers on ways to support nerve repair and restore function after damage to the nervous system. Its lead investigational product, NVG-291, is a peptide designed to target a protein involved in limiting nerve repair. NervGen has studied the candidate for spinal cord injury and is exploring its potential in other conditions involving nervous system damage.

Further Reading

Analyst Recommendations for NervGen Pharma (NASDAQ:NGEN)

Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.